DOI: 10.12890/2025_005604

Diagnostic and therapeutic paradoxes in PCR-positive, histopathology-negative CNS aspergillosis in a patient with HIV and Hodgkin lymphoma

Authors

  • Nikolas Kenaya Department of Internal Medicine, Wayne State University School of Medicine, Trinity Health Oakland Hospital, Pontiac, USA
  • Joshua Hermiz Department of Internal Medicine, Wayne State University School of Medicine, Trinity Health Oakland Hospital, Pontiac, USA
  • Joshua Hailo Department of Internal Medicine, Wayne State University School of Medicine, Detroit Medical Center, Detroit, USA
  • Zahra Chehab Department of Internal Medicine, Wayne State University School of Medicine, Detroit Medical Center, Detroit, USA
  • Emelia Johnson Department of Internal Medicine, Wayne State University School of Medicine, Trinity Health Oakland Hospital, Pontiac, USA
  • Christian Toquica Gahona Department of Internal Medicine, Wayne State University School of Medicine, Trinity Health Oakland Hospital, Pontiac, USA
  • Saba Asif Department of Internal Medicine, Wayne State University School of Medicine, Trinity Health Oakland Hospital, Pontiac, USA

Joshuahermiz18@gmail.com

Keywords

CNS Aspergillosis, Hodgkin lymphoma, human immunodeficiency virus, adverse drug reactions, Torsades de Pointes

Abstract

Background: Invasive central nervous system (CNS) aspergillosis is rare among human immunodeficiency virus (HIV)-positive patients due to preserved neutrophil function, despite significant CD4+ T-cell depletion. Diagnosis typically requires histopathologic confirmation, but polymerase chain reaction (PCR) testing has introduced new challenges due to its high sensitivity but limited specificity.
Case presentation: We describe a newly diagnosed 43-year-old HIV-positive male with concurrent Hodgkin lymphoma who presented with progressive neurological decline and a ring-enhancing brain lesion. While histopathological analysis of the brain biopsy demonstrated features of HIV-associated leukoencephalopathy, PCR testing paradoxically identified Aspergillus fumigatus; however, histopathological examination failed to demonstrate definitive fungal elements. Despite negative cerebrospinal fluid galactomannan and ß-D-glucan assays, empiric voriconazole therapy was initiated in accordance with current treatment guidelines. Over the ensuing month, the patient returned with worsening neurologic status, radiographic lesion progression, and ultimately developed Torsades de Pointes, and multiorgan failure, resulting in death.
Discussion: This case underscores the diagnostic and therapeutic complexities of PCR-positive, histopathology-negative CNS aspergillosis in HIV. Overreliance on molecular results without confirmatory pathology may lead to unnecessary antifungal therapy and severe drug toxicity. Additionally, overlapping immunosuppressive conditions—such as HIV and lymphoma—complicate clinical interpretation and management.
Conclusion: In HIV-positive patients with CNS lesions, PCR detection of Aspergillus should not independently justify antifungal therapy. Histological confirmation and multidisciplinary evaluation are essential to avoid misdiagnosis and adverse outcomes. This case highlights the urgent need for more precise treatment guidelines on when to initiate and discontinue antifungal treatment in complex immunocompromised populations.

View the entire article

Downloads

References

  1. Mühlemann K, Wenger C, Zenhäusern R, Täuber MG. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 2005;19:545-50. doi: 10.1038/sj.leu.2403674
  2. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. NIH, HIV Medicine Association, and Infectious Diseases Society of America. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection. Accessed (April 2025).
  3. Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;63:e1-e60. doi: 10.1093/cid/ciw326
  4. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-1821. doi: 10.1086/588660
  5. Mylonakis E, Paliou M, Sax PE, Skolnik PR, Baron MJ, Rich JD. Central nervous system aspergillosis in patients with human immunodeficiency virus infection. Report of 6 cases and review. Medicine (Baltimore) 2000;79:269-280. doi: 10.1097/00005792-200007000-00008
  6. Grewal R, Irimie A, Naidoo N, Mohamed N, Petrushev B, Chetty M, et al. Hodgkin’s lymphoma and its association with EBV and HIV infection. Crit Rev Clin Lab Sci 2018;55:102-114. doi: 10.1080/10408363.2017
  7. Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005;106:2641-2645. doi: 10.1182/blood-2005-02-0733

Published

2025-08-13

How to Cite

1.
Kenaya N, Hermiz J, Hailo J, Chehab Z, Johnson E, Toquica Gahona C, et al. Diagnostic and therapeutic paradoxes in PCR-positive, histopathology-negative CNS aspergillosis in a patient with HIV and Hodgkin lymphoma. EJCRIM [Internet]. 2025 Aug. 13 [cited 2026 Nov. 3];12(9). Available from: https://ejcrim.com/index.php/ejcrim/article/view/5604

Most read articles by the same author(s)